Innoviva Inc. (INVA)
18.18
0.30 (1.68%)
At close: Mar 28, 2025, 3:59 PM
18.22
0.25%
After-hours: Mar 28, 2025, 05:34 PM EDT
1.68% (1D)
| Bid | 17 |
| Market Cap | 1.14B |
| Revenue (ttm) | 365.33M |
| Net Income (ttm) | 23.37M |
| EPS (ttm) | 0.36 |
| PE Ratio (ttm) | 50.49 |
| Forward PE | 9.99 |
| Analyst | Buy |
| Ask | 19 |
| Volume | 608,970 |
| Avg. Volume (20D) | 766,646 |
| Open | 17.92 |
| Previous Close | 17.88 |
| Day's Range | 17.84 - 18.34 |
| 52-Week Range | 14.33 - 21.28 |
| Beta | 0.57 |
About INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2004
Employees 127
Stock Exchange NASDAQ
Ticker Symbol INVA
Website https://www.inva.com
Analyst Forecast
According to 2 analyst ratings, the average rating for INVA stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 202.61% from the latest price.
Stock ForecastsNext Earnings Release
Innoviva Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
